Skip to main content
OpenTrials

Clinical trial condition

Stage III Bladder Cancer AJCC v8

Explore clinical trials studying Stage III Bladder Cancer AJCC v8. Study availability and eligibility vary by location and protocol.

16 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Stage III Bladder Cancer AJCC v8 trial results

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

NCT05756569

Conditions
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Female Urogenital Diseases, +22 more
Locations
  • Grady Health System Atlanta, Georgia, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Emory Saint Joseph's Hospital Atlanta, Georgia, United States
View Trial Details
Completed

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952

Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Carcinoma, +40 more
Locations
  • Kaiser Permanente-Riverside Riverside, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Straub Clinic and Hospital Honolulu, Hawaii, United States
  • University of Hawaii Cancer Center Honolulu, Hawaii, United States
View Trial Details
Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

NCT03617913

Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +24 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

NCT05092958

Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, +30 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Sutter Auburn Faith Hospital Auburn, California, United States
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
  • Palo Alto Medical Foundation-Fremont Fremont, California, United States
View all 275 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
View all 34 locations
View Trial Details

Related conditions